Daily Ischemic Preconditioning Provides Sustained Protection From Ischemia–Reperfusion Induced Endothelial Dysfunction: A Human Study

• Published in: Journal of the American Heart Association 2013-02, Vol.2 (1), p.e000075-n/a
• Main Authors: Luca, Mary Clare, Liuni, Andrew, McLaughlin, Kelsey, Gori, Tommaso, Parker, John D.
• Format: Article
• Language: English
• Subjects: Adult; Analysis of Variance; Celecoxib; Cross-Over Studies; Cyclooxygenase 2 - metabolism; Cyclooxygenase 2 Inhibitors - pharmacology; cyclooxygenase‐2; endothelium; Endothelium, Vascular - drug effects; Endothelium, Vascular - enzymology; Endothelium, Vascular - physiopathology; Forearm - blood supply; Humans; Hyperemia - physiopathology; ischemia; ischemic preconditioning; Ischemic Preconditioning - methods; Male; Ontario; Original Research; Pyrazoles - administration & dosage; reperfusion; Reperfusion Injury - enzymology; Reperfusion Injury - physiopathology; Reperfusion Injury - prevention & control; Sulfonamides - administration & dosage; Time Factors; Vasodilation - drug effects; Young Adult
• ISSN: 2047-9980; 2047-9980
• DOI: 10.1161/JAHA.112.000075

Background It is well established that acute ischemic preconditioning (IPC) protects against ischemia–reperfusion (IR) injury; however, the effectiveness of repeated IPC exposure has not been extensively investigated. We aimed to determine whether daily IPC episodes provide continued protection from IR injury in a human forearm model, and the role of cyclooxygenase‐2 in these responses. Methods and Results Thirty healthy volunteers were randomized to participate in 2 of 3 protocols (IR alone, 1‐day IPC, 7‐day IPC) in an operator‐blinded, crossover design. Subjects in the IR alone protocol underwent flow‐mediated dilation (FMD) measurements pre‐ and post‐IR (15′ upper‐arm ischemia and 15′ reperfusion). The 1‐day IPC protocol involved FMD measurements before and after 1 episode of IPC (3 cycles of 5′ upper‐arm ischemia and 5′ reperfusion) and IR. Day 7 of the 7‐day IPC protocol was identical to the 1‐day IPC protocol but was preceded by single daily episodes of IPC for 6 days prior. During each protocol, subjects received a 7‐day treatment of either the cyclooxygenase‐2 inhibitor celecoxib or placebo. Pre‐IR FMD was similar between groups. IR alone reduced FMD post‐IR (placebo, ΔFMD: −4.4±0.7%; celecoxib, ΔFMD: −5.0±0.5%). One‐day IPC completely prevented this effect (placebo, ΔFMD: −1.1±0.6%; celecoxib, ΔFMD: 0.0±0.7%; P